Supplemental materials.

Figure S1. Participant-level clinical data




Figure S1. Viral kinetics of rebound after ATI in A5340 are shown for each participant, with the highest measure indicating peak viral load prior to suppression upon re-initiation of ART. The number of years on suppressive ART prior to A5340 trial entry for each participant is shown in inset.

Fig S2. Between marker associations

IUMP (log10 ug/ml)




Figure S1. Spearman correlations between total DNA, caRNA and replication competent virus. Pairwise correlations between total HIV-1 DNA, caRNA, and frequency of cells bearing replication competent virus (IUPM) are shown pre-ATI (A), post-ATI (B), and for the log10 change over ATI (C). There is some evidence suggesting the correlation between HIV-1 total DNA and IUPM pre-ATI (Spearman correlation 0.68, P=0.06), post-ATI (Spearman correlation 0.83, P=0.01), and in change between timepoints (Spearman correlation 0.79, P=0.02).

Total DNA (log10 cp/million CD4 cells)

IUMP (log10 ug/ml)




Figure S2. Single copy assay. Single copy assay was performed to detect low-level viremia in plasma collected during suppressive ART before and after the trial. With a limit of detection of <0.5 copies/ml, 3 participants remained undetectable before and after ATI, 3 participants were above detectable at both timepoints, 1 participant went from just above detection (0.53 c/ml) to undetectable, while the remaining 2 went from undetectable to 2.14 and 2.19 copies/ml, respectively.

Fig S4. Comparison of pairwise Levenshtein Distances.




Figure S5. Comparisons of pairwise Levenshtein Distances between virus populations. For each participant, pairwise Levenshtein edit distance between nucleotide sequences sets are shown. Rebound sequences are labeled R, QVOA sequences are labeled Q, Proviral DNA sequences are labeled C, and pre-ART sequences are labeled PC. In the box on the left, comparisons between viruses from each timepoint are shown (i.e., Q1 is pre-ATI QVOA sequences and Q2 is post-ATI QVOA sequences). In the box on the left, sequences from the pre- and post-ATI samples are combined. Statistical significance by PERMANOVA after Bonferroni correction for multiple comparisons is indicated by the heat map.

TREND Statement Checklist

Paper Section/ Topic	Item	Descriptor	Reported?	
	No		\checkmark	Pg #
Title and Abst	ract			
Title and	1	Information on how unit were allocated to interventions	Х	17
Abstract		Structured abstract recommended	Х	2
		Information on target population or study sample	Х	3
Introduction				
Background	2	Scientific background and explanation of rationale	X	3-4
0		Theories used in designing behavioral interventions	NA	
Methods				
Participants	3	Eligibility criteria for participants, including criteria at different levels in		
	Ū	recruitment/sampling plan (e.g., cities, clinics, subjects)	Х	17
		 Method of recruitment (e.g., referral, self-selection), including the 		
		sampling method if a systematic sampling plan was implemented	Х	17
		Recruitment setting	Х	17
		Settings and locations where the data were collected	Х	17
Interventions	4	• Details of the interventions intended for each study condition and how	v	17
		and when they were actually administered, specifically including:	X	1/
		 Content: what was given? 		
		 Delivery method: how was the content given? 		
		 Unit of delivery: how were the subjects grouped during delivery? 		
		 Deliverer: who delivered the intervention? 		
		 Setting: where was the intervention delivered? 		
		 Exposure quantity and duration: how many sessions or episodes or events were intended to be delivered? How long were they 		
		intended to last?		
		 Time span: how long was it intended to take to deliver the 		
		intervention to each unit?		
		 Activities to increase compliance or adherence (e.g., incentives) 		
Objectives	5	Specific objectives and hypotheses	Х	4
Outcomes	6	Clearly defined primary and secondary outcome measures	NA	
		 Methods used to collect data and any methods used to enhance the quality of measurements 	x	17-21
		 Information on validated instruments such as psychometric and biometric properties 	NA	
Sample Size	7	How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules	NA	
Assignment Method	8	 Unit of assignment (the unit being assigned to study condition, e.g., individual, group, community) 	NA	
		 Method used to assign units to study conditions, including details of any restriction (e.g., blocking, stratification, minimization) 	NA	
		 Inclusion of aspects employed to help minimize potential bias induced due to non-randomization (e.g., matching) 	NA	

TREND Statement Checklist

I KEND State				1
Blinding (masking)	9	 Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to study condition assignment; if so, statement regarding how the blinding was accomplished and how it was assessed. 	NA	
Unit of Analysis	10	 Description of the smallest unit that is being analyzed to assess intervention effects (e.g., individual, group, or community) 	NA	
		 If the unit of analysis differs from the unit of assignment, the analytical method used to account for this (e.g., adjusting the standard error estimates by the design effect or using multilevel analysis) 	NA	
Statistical Methods	11	 Statistical methods used to compare study groups for primary methods outcome(s), including complex methods of correlated data 	х	17-21
		 Statistical methods used for additional analyses, such as a subgroup analyses and adjusted analysis 	NA	
		Methods for imputing missing data, if used	NA	
		Statistical software or programs used	Х	17-21
Descrite				
Results Participant flow	12	• Flow of participants through each stage of the study: enrollment, assignment, allocation, and intervention exposure, follow-up, analysis (a	NA	
		diagram is strongly recommended)		
		 Enrollment: the numbers of participants screened for eligibility, 		
		found to be eligible or not eligible, declined to be enrolled, and enrolled in the study		
		 Assignment: the numbers of participants assigned to a study condition 		
		 Allocation and intervention exposure: the number of participants assigned to each study condition and the number of participants who received each intervention 		
		 Follow-up: the number of participants who completed the follow- up or did not complete the follow-up (i.e., lost to follow-up), by study condition 		
		 Analysis: the number of participants included in or excluded from the main analysis, by study condition 		
		 Description of protocol deviations from study as planned, along with reasons 		
Recruitment	13	Dates defining the periods of recruitment and follow-up	Х	17
Baseline Data	14	Baseline demographic and clinical characteristics of participants in each study condition	х	4-5
		 Baseline characteristics for each study condition relevant to specific disease prevention research 	NA	
		 Baseline comparisons of those lost to follow-up and those retained, overall and by study condition 	NA	
		 Comparison between study population at baseline and target population of interest 	NA	
Baseline equivalence	15	• Data on study group equivalence at baseline and statistical methods used to control for baseline differences	NA	

TREND Statement Checklist

Numbers analyzed	16	• Number of participants (denominator) included in each analysis for each study condition, particularly when the denominators change for different outcomes; statement of the results in absolute numbers when feasible	NA	
		 Indication of whether the analysis strategy was "intention to treat" or, if not, description of how non-compliers were treated in the analyses 	NA	
Outcomes and estimation	17	• For each primary and secondary outcome, a summary of results for each estimation study condition, and the estimated effect size and a confidence interval to indicate the precision	NA	
		Inclusion of null and negative findings	Х	
		 Inclusion of results from testing pre-specified causal pathways through which the intervention was intended to operate, if any 	NA	
Ancillary analyses	18	• Summary of other analyses performed, including subgroup or restricted analyses, indicating which are pre-specified or exploratory	NA	
Adverse events	19	 Summary of all important adverse events or unintended effects in each study condition (including summary measures, effect size estimates, and confidence intervals) 	NA	
DISCUSSION				
Interpretation	20	• Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study	x	12-17
		 Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations 	NA	
		• Discussion of the success of and barriers to implementing the intervention, fidelity of implementation	NA	
		Discussion of research, programmatic, or policy implications	Х	12-17
Generalizability	21	• Generalizability (external validity) of the trial findings, taking into account the study population, the characteristics of the intervention, length of follow-up, incentives, compliance rates, specific sites/settings involved in the study, and other contextual issues	x	16-17
Overall Evidence	22	General interpretation of the results in the context of current evidence and current theory	х	16-17

From: Des Jarlais, D. C., Lyles, C., Crepaz, N., & the Trend Group (2004). Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. *American Journal of Public Health*, 94, 361-366. For more information, visit: <u>http://www.cdc.gov/trendstatement/</u>